Immune checkpoint inhibitor therapy in advanced head and neck cancer
10.3760/cma.j.issn.1673-0860.2017.01.015
- VernacularTitle: 免疫检查点抑制剂治疗晚期头颈部恶性肿瘤的研究进展
- Author:
Wei HANG
1
;
Zhixiang XU
2
;
Qiang ZHANG
1
;
Xing LU
1
;
Gang LIU
1
Author Information
1. Department of Otorhinolaryngology Head and Neck Surgery, Tianjin HuanHu Hospital, Tianjin 300350, China
2. Division of Hematology and Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA
- Publication Type:Review
- Keywords:
Head and neck neoplasms;
PD-1;
PD-L1;
CTLA-4;
Immune Checkpoint;
Immunotherapy
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2017;52(1):67-70
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitor therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, improves the life quality of cancer patients and has joined the ranks of surgery, radiation, and chemotherapy to become a major choice for cancer therapy. Over the past few years, multiple exciting results have been obtained on checkpoint inhibitor therapy in advanced head and neck cancer. However, questions such as patient selection and biomarkers for assessing the therapy are largely unsolved. Herein, we briefly review recent findings in checkpoint inhibitor therapy for advanced head and neck cancer. We will also discuss possible mechanism, safety, combination therapy, and side effects for the therapy. Checkpoint inhibitor therapy has led to important clinical advances and will provide a new weapon against cancer.
